Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1).

Luo, Dongcheng; Liao, Sina; Li, Qian; Lin, Youzhi; Wei, Junbao; Li, Yongqiang; Liao, Xiaoli

Luo, Dongcheng; Liao, Sina; Li, Qian; Lin, Youzhi; Wei, Junbao; Li, Yongqiang; Liao, Xiaoli.

Afiliación

Luo D; Department of First Chemotherapy, Guangxi Medical University Cancer Hospital, Nanning, China.
Liao S; Department of First Chemotherapy, Guangxi Medical University Cancer Hospital, Nanning, China.
Li Q; Department of First Chemotherapy, Guangxi Medical University Cancer Hospital, Nanning, China.
Lin Y; Hepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Wei J; Radiotherapy Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Li Y; Department of First Chemotherapy, Guangxi Medical University Cancer Hospital, Nanning, China.
Liao X; Department of First Chemotherapy, Guangxi Medical University Cancer Hospital, Nanning, China.

Front Oncol ; 12: 862600, 2022.

Article en En | MEDLINE | ID: mdl-35847852

Palabras clave

TS-1; advanced pancreatic cancer; anlotinib; chemotherapy; gimeracil and oteracil potassium capsules; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google